Advanced Search

 

Study ID Status Title Patient Level Data
SLGH10 Completed A Double-Blind Cross-Over Study to Determine if 50mcg Inhaled GR33343G (salmeterol) Twice Daily Compared With Salbutamol for 13 Days Caused Tachyphylaxis in Patients With Stable Asthma
SLGH11 Completed A Single-Centre, Randomised, Double-Blind, Cross-Over Study to Compare the Efficacy of Metered-Dose Inhaler and Dry Powder Formulations of GR33343G With That of Salbutamol Inhaler and Placebo in Patients With Asthma
SLGH12 Completed A Single-Dose, Double-Blind, Cross-Over Study to Determine the Efficacy and Duration of Action of Inhaled GR33343G 50mcg, as Metered-Dose Inhaler or Dry Powder, Against Histamine-Induced Bronchoconstriction
SLGH13 Completed To Compare the Effects of Salmeterol and Salbutamol on Speed of Recovery From Methacholine-Induced Bronchoconstriction in Patients With Reversible Airways Disease
SLGH14 Completed To Determine the Duration of Action of Inhaled GR33343G (salmeterol) (50mcg and 100mcg) Against Methacholine-Induced Bronchoconstriction in Patients With Mild to Moderate Reversible Airways Obstruction
SLGH15 Completed A Single-Dose, Double-Blind, Placebo-Controlled, Randomised, Cross-Over Study to Determine the Effect of Salmeterol (50mcg via Metered-Dose Inhaler) on Immediate- and Late-Phase Allergen-Induced Bronchoconstriction and Bronchial Hyper-Responsiveness
SLGH17 Completed A Single-Centre, Double-Blind, Randomised, Cross-Over Study to Determine the Duration of Action of Salmeterol Administered From a Metered-Dose Inhaler Against Exercise-Induced Bronchospasm in Patients With Asthma
SLGH18 Completed A Cumulative Dosing, Double-Blind, Double-Dummy, Cross-Over Study to Compare the Efficacy of 175mcg GR33343G Administered by 4-Place Diskhaler With 175mcg GR33343G Administered by 8-Place Diskhaler in Asthmatic Patients
SLGH30 Completed A Study to Determine the Duration of Action of Inhaled Salmeterol During Exercise Challenge Tests in Asthmatic Children
SLGH42 Completed A Study to Determine the Effects of Chronic Dosing With Inhaled Salmeterol on Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease
SLGL17 Completed A Single Centre, Randomised, Double-Blind, Cross-Over Study to Compare the Efficacy of Inhaled Salmeterol Xinafoate Dry Powder 50mg BID via the Diskhaler with Placebo Dry Powder BID via the Diskhaler in the Treatment of Non-Reversible COPD Patients and to Provoke with Histamine and…
SLGL24 Completed A double-blind, randomised, parallel group study to investigate the efficacy of inhaled salmeterol 50?g administered twice daily compared with salbutamol 200?g administered four times daily in patients with poorly controlled nocturnal asthma.
SLGL82 Completed A double-blind parallel group study of inhaled salmeterol in asthmatic patients
SLGQ08/SLM8905 Completed An eight week randomized, double-blind, parallel group study to compare efficacy of salmeterol 50mcg BID, beclomethasone dipropionate 400mcg BID and salmeterol 50mcg plus beclomethasone dipropionate 400mcg BID in subjects with allergic asthma
SLGQ94 (521/180) Completed A multicenter, randomized, double-blind, parallel-group trial to evaluate the long-term efficacy and safety of inhaled salmeterol 50mg BID compared to short-acting b2-agonists as-needed in adult patients with asthma.
SLGQ98 Completed A 12 week randomized, double-blind, parallel group study evaluating effect of fluticasone propionate 500mcg BID, fluticasone propionate 200mcg plus salmeterol 50mcg BID or fluticasone propionate 200mcg BID for control of airway inflammation in subjects with asthma.
SLGS04 Completed A 12 week randomized, double-blind, parallel group study evaluating effect of salmeterol 50mcg BID or fluticasone propionate 100mcg BID for control of airway inflammation in subjects with asthma, when added to current inhaled corticosteroid therapy.
SLGS05 Completed Dose Response to Inhaled Salmeterol in Chronic Obstructive Pulmonary Disease
SLGS06 Completed A Single-Centre, Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study to Compare the Efficacy and Safety of Salmeterol Xinafoate (100mg BID) with that of Placebo BID in Patients with Chronic Obstructive Pulmonary Disease
SLGT01 Completed A Multi-centre, 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study of 3 Twice-Daily Dosage Schedules of Inhaled GR33343G In Patients With Mild to Moderate Reversible Airways Obstruction
SLGT02 Completed Inhaled GR33343G In Reversible Airways Obstruction – Efficacy Over 3 Months and Safety Over 12 Months.
SLGT03 Completed A Double-Blind, Double-Dummy, Randomised, Multi-centre, Cross-over Study to Compare the Relative Efficacy of, and Tolerance to, 50mcg Inhaled GR33343G With Individually Dose-Titrated, Sustained-Release Theophylline (THEODUR®), Administered 12-Hourly, in Patients With Moderate Reversible Airways ...
SLGT04 Completed A Multi-centre, Randomised, Parallel-Group, Double-Blind Study Comparing Inhaled GR33343G 50mcg and 100mcg Twice Daily for 3 Months in Patients With Moderate to Severe Reversible Airways Obstruction
SLGT05 Completed Assessment of the Comparability of Metered-Dose Inhaler and Dry Powder Formulations of 50mcg GR33343G, Administered Twice Daily for 2 Weeks to Patients with Mild to Moderate Reversible Airways Obstruction.
SLGT06 Completed Inhaled GR33343G in Reversible Airways Obstruction – Efficacy and Safety Over Three Months: A Double-Blind, Parallel-Group Study Comparing Dry Powder Formulations of Inhaled GR33343G (50mcg) Administered Twice a Day and Inhaled Salbutamol (400mcg) Administered Four Times a Day

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.